wise not to change the laboratory routine and depart from the established blood bank practice; it will provide that extra confirmation that the correct blood is being returned to the donor. Meticulous attention to identification and record-keeping, both in the laboratory and in the patient's notes, may make this additional precaution unnecessary; local policy will dictate what is required.
The recent fears of HIV, and the understandable concern of many patients about receiving blood, now prompt a reappraisal ofautologous blood. Besides the fear of HIV transmission, there is a need to consider the effect of homologous blood on the recurrence of colonic cancer, an interesting but unproven claim 1B -2 0 • It seems likely that future blood transfusion practice will make increasing use of this technique, and indeed patients having an elective surgical procedure may insist on it. We should be prepared to meet this demand: it will conserve donor blood for those who need it, particularly the emergency case, and should result in better use of our blood supplies. Nowhere would this be truer than in developing countries, where it is very difficult to obtain an adequate supply of donor blood.
Autologous components will make an important contribution to the blood supply. Total commitment of those involved will be required to establish and maintain an ABT programme, but it is anticipated that the demand and advantages will outweigh the disadvantages. With the introduction of clinical budgeting and the possibility of being charged for the blood we use, ABT may prove to have economic advantages as well". In addition, any autologous transfusion programme must be closely associated with, and complementary to, our well-established NBTS, which will be the organization responsible for maintaining these high standards essential for the safety of all who receive a blood transfusion 3 • 2 1 • The medical profession will need to be educated to provide the safest blood for their patients. It is logical to promote and to proceed with the implementation of an autologous blood transfusion service. Medicinal therapy grows in sophistication continually; the new drugs interfere deeply, subtly and strongly with body systems. This is reflected by the ways in which modern therapy influences and assumes homeostatic controls. They require for their successful use careful monitoring by an informed prescriber. It is reflected also by the increasing and frequent discovery ofdrug actions and effects beyond those for which those drugs were licensed. In such times, it might be expected reasonably that clinical pharmacology, the discipline and the specialty, would grow vigorously. That this is not wholly the case was emphasized at the Anglo-American Workshop on Clinical Pharmacology, held in Airlie, Virginia, in May 1984 and sponsored by the American Society for Pharmacology and Experimental Therapeutics, the Burroughs Wellcome Fund, the Royal Society of Medicine and the Royal Society of Medicine Foundation Inc. Though the discipline of clinical pharmacology was exemplified over many years by the research of a few enthusiastic individuals who made illuminating studies of drug effects related to dose 1 , and who revealed some surprising drug actions in well-designed experiments and clinical trials, it gained established recognition only in the mid-1960s in Britain", It grew quite rapidly at first. But growth is now halted, before its full potential as a specialty has been realized 3 • Why has this happened? As if focusing down to reveal increasing detail, one can surmise reasons at several levels. At the broadest level the overall reason could well be economic. A subject born, in terms of establishment, in the boom days of the mid-1960s will be the most vulnerable as soon as the inevitable retrenchment sets in, unless it can command resources because it outvalues its competitors. At a more detailed economic level more specific reasons appear. Its natural dependence upon 'soft' money grants from the drug industry, a strong advantage in days of plenty, becomes a most constricting influence when industry turns naturally from 'no strings attached' grants to strictly project-oriented grants; funds lessen as effective product patent life falls and regulatory requirements become more demanding", This constriction affects not only funds, but also the academic opportunity to quest and question freely which a truly scientific development needs. It forces all research more and more towards the Rothschild-type of consumer-contractor pattern. At the same level of detail, when there is retrenchment big academic battalions engage in resource capture; smaller disciplines are absorbed back into their larger parents by a sort of 'soap bubble effect'. Young doctors do not want to train in a specialty with uncertain career prospectst", so resources are further withdrawn from a specialty which has to close training posts. This is especially true when, in a new subject, new posts are filled quickly by young applicants leaving no promotion prospects for many years", All arguments at this level are economic; they are matters of supply and demand, and in their basic drives have little to do with the subject itself, with its potential contributions or with medical needs, whether in practice, education or research.
As one focuses down, still more reasons for developmental arrest in this subject appear. Academic units are small and so are peculiarly vulnerable to the critical mass effect as staff are lost. This is particularly true when, as in clinical pharmacology, there is heavy dependence on laboratory research, xenobiotic analysis and technical help". It seems true that research in the discipline has lost the sharp spirit of enquiry of its earliest exponents; there has been a lot of detailed, uncontributory pharmacokinetic research!", often unrelated to pharmacodynamics. But this stricture should not obscure the question of why this kind of research has become so prominent, nor the fact that much excellent work has been done to reveal the remarkable complexity of many pharmacokinetic effects, and how subtly different they are from what had been supposed. Examples are the demise of protein binding as the explanation of some major anticoagulant interactions, and the exploration of the inherited oxidative polymerphisms. The reasons for the repetitive work certainly include the critical mass effect, and the policies and reduced funding power of granting agencies. It is odd indeed, when drug actions involve so many psychotropic effects and so affect quality of life, that studies which include measures of these effects are most unlikely to attract funding, especially from the research councils. There is much adherence to the Journal ofthe Royal Society of Medicine Volume 80 May 1987 269 'hard-soft' science distinction, as if drug effects did not concern people, but only chemicals, or only the mindless body.
At the most intimate level, there are reasons for halted growth within the subject itself. It lacks the automatic specialty-generating identity kit of a specific organ, or instrument or technique. Like psychiatry, it is something which anyone can do; the fact that they do not do it escapes attention. A clinical pharmacologist is, in a sense, always commenting implicitly upon what other people should be doing; this means that a clinical pharmacologist must be a diplomat if nothing else. Students expect course material in the subject to be a simple, didactive presentation of fact. They are not prepared for therapeutic choice, for the controversy of gains and losses from drug effects.
What then of the future? If the past is to be explained in terms of environmental pressures upon a subject, the future can be gained only ifits exponents justify its, and their, existence by demonstrating the value of their discipline. This will not be done in simple terms of direct value, of contracts completed or of services rendered, important though these contributions are, but in terms of new ideas which influence the practice of medicine. The discipline will surely survive; there will always be people who can see the strong relevance of clinical pharmacology to medicinal therapy as well as to new drug development. The clinical section of the British Pharmacological Society grows steadily, and the British Journal of Clinical Pharmacology flourishes. Research is reported both at meetings and in the journal which illuminates medical practice.
But what of clinical pharmacology as a specialty? It is a matter for concern that, in Britain at least, it may become confined to a few large university departments through the critical mass effects of the new selective system of university funding'; the effect of this is 'to those who have will be given', and 'those who have' are defined effectively as those whose grant applications conform to the channels laid down by those who have had and still have. This system is good in the sense that it helps to crack the big, important and costly problems, using new and expensive techniques. It is bad in the way in which it eliminates the tender shoots of new growth which are the stuff of scientific advance, but which remain of 'doubtful significance'. And it is particularly bad for small departments like many of those in clinical pharmacology. The way forward must indeed include the pursuit of excellent, basic, collaborative research", but this cannot be the whole story. There is great loss in pursuing main lines whilst failing to notice where their branches point, especially in clinical medicine. There can be no doubt about the vigour and enthusiasm within clinical pharmacology, but equally no doubt about its failure to gain appreciation outside itself. Ifthe specialty was born in Britain in a boom, it is sad that the first generation ofspecialists who were trained within it came to look for consultant posts at the time of subsequent retrenchment. It is equally unfortunate that a reduced cadre of clinical pharmacologists is now faced with the task of making bricks without straw; as medicines become more sophisticated, research costs escalate relentlessly through increased development times, reduced effective patent lives, extended regulatory requirements, more stringent ethical review", and the rapid rise in in aur-ance premiums driven by the United States market. Volunteer and clinical studies of a number of muchneeded advances in medicinal therapy, especially in the case of vaccines, biodegradable prostheses and some products of genetic engineering or peptide synthesis, are becoming uninsurable in the USA, and may soon do so in other countries including Britain. This is happening not because clinical pharmacological research is very hazardous", but because it is perceived to be so outside the medical community.
It is possible to envisage several fates for clinical pharmacology short of extinction. It could become an enclave of industry, for it will always remain essential for new drug development. It could, as in the United States!", become confined largely to industry and to research departments in universities which contribute little to teaching or to the general clinical care of patients, unless they suffer from rare, obscure or biochemically important disorders. Or it may remain, as now in the United Kingdom, contributing to new drug development, to research, to teaching and (in some places) to patient care. No doubt its eventual place will be the result of market forces -the wealth needed to fund it, and the value placed upon it by the Health Service and universities. Clinical pharmacologists can do little to influence wealth, but they can influence the value set upon their efforts by the community. If so, much remains for them to do. Clinical pharmacology suffers from ignorance about its potential contributions, and to some degree a failure by its proponents to tackle important questions. But the current status of the discipline in most parts of Britain, both as regards funding and opportunity, makes basic work difficult.
Perhaps clinical pharmacology suffers, like many other disciplines within medicine, from an environment which cannot understand applied biology; but because it cannot make the dramatic contributions open to some others. it is-at its present growth stageat one of medicine's most vulnerable points.
Its sister discipline of toxicology seems similarly placed. Perhaps the most pressing need, if the future contribution of the subject is to be guaranteed, is for its exponents to explain xenobiotica to those around who fail to understand it, rather than only to one another.
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